Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors

NCT05194735 ↗

Phase 1/2 Terminated 8 enrolled Alaunos Therapeutics

Non-randomizedSequentialOpen-labelTreatment

Summary

A Phase I/II study of autologous T cells engineered using the Sleeping Beauty transposon/transposase system to express TCR(s) reactive against neoantigens in subjects with relapsed/refractory solid tumors

Timeline

Start: 2022-04-04
Primary completion: 2023-08-14
Completion: 2023-08-14

Publications

Levy PL, Gros A. Fast track to personalized TCR T cell therapies. Cancer Cell. 2022 May 9;40(5):447-449. doi: 10.1016/j.ccell.2022.04.013. Epub 2022 May 9.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Neoantigen specific TCR-T cell drug product	Cell therapy	—	Intravenous
Background	aldesleukin	Protein / enzyme biologic	—	—

Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors

Summary

Timeline

Publications

Drugs

Indications